http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 06:40:39 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Teleflex+%28TFX%29+PT+Raised+to+%24145+at+Mizuho/26770544.html Mizuho analyst Anthony Petrone raised the price target on Teleflex (NYSE: TFX) to $145.00 (from $140.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Teleflex+%28TFX%29+PT+Raised+to+%24145+at+Mizuho/26770544.html Wed, 15 Jul 2026 06:40:39 -0400 TFX http://www.streetinsider.com/New+Coverage/BMO+Capital+Starts+Teleflex+%28TFX%29+at+Outperform/26747647.html <p>BMO Capital initiates coverage on Teleflex (NYSE: TFX) with a Outperform rating.</p><p>For an analyst ratings summary and ratings history on Teleflex <a href="http://www.streetinsider.com/rating_history.php?q=TFX">click here</a>. For more ratings news on Teleflex <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TFX&amp;type=analyst">click here</a>.</p><p>Shares of Teleflex closed at $133.54 yesterday.</p> http://www.streetinsider.com/New+Coverage/BMO+Capital+Starts+Teleflex+%28TFX%29+at+Outperform/26747647.html Wed, 08 Jul 2026 16:10:22 -0400 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Press+Releases/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html <p class="bwalignc"> <i>Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). </p><p> “This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for http://www.streetinsider.com/Business+Wire/Teleflex+Publishes+2025+Global+Impact+Report/26738034.html Tue, 07 Jul 2026 06:30:00 -0400 A.60012006 A.60012011 O.00001053 O.31403954 O.37892119 TFX http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++TELEFLEX+INC++++++++++++++For%3A+Dec+31/26698526.html si-local-file:///var/storage/secattach/20260626/26698526.html http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++TELEFLEX+INC++++++++++++++For%3A+Dec+31/26698526.html Fri, 26 Jun 2026 15:52:00 -0400 O.00001053 TFX http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++TELEFLEX+INC++++++++++++++For%3A+Dec+31/26698526.html si-local-file:///var/storage/secattach/20260626/26698526.html http://www.streetinsider.com/SEC+Filings/Form++11-K+++++++TELEFLEX+INC++++++++++++++For%3A+Dec+31/26698526.html Fri, 26 Jun 2026 15:52:00 -0400 O.00001053 TFX http://www.streetinsider.com/Corporate+News/Teleflex+starts+global+pivotal+trial+for+resorbable+magnesium+scaffold/26675516.html <p>Teleflex Incorporated (NYSE: TFX) has initiated enrollment in the BIOMAG-III Study, a global pivotal trial evaluating the Freesolve Resorbable Magnesium Scaffold (RMS) for treating narrowed coronary arteries.</p><p>The first patient in the U.S. investigational device exemption (IDE) trial was enrolled at MedStar Health in Washington, D.C., with Dr. Itsik Ben-Dor performing the implant. The randomized controlled trial plans to enroll 1,859 patients across up to 120 sites worldwide, including up to 60 U.S. locations. The study will compare Freesolve RMS to the Xience Drug-Eluting Stent, measuring Target Lesion Failure rates at 12 months. Scaffold lengths up to 40mm will be included.</p><p>Teleflex http://www.streetinsider.com/Corporate+News/Teleflex+starts+global+pivotal+trial+for+resorbable+magnesium+scaffold/26675516.html Tue, 23 Jun 2026 06:30:33 -0400 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html <p class="bwalignc"> <i>Enrollment completed ahead of schedule in BIOMAG™-II</i> </p><p class="bwalignc"> <i>Positive four-year BIOMAG™-I results recently reported</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290&amp;esheet=54558134&amp;newsitemid=20260623597311&amp;lan=en-US&amp;anchor=NCT07258290&amp;index=1&amp;md5=96a5d16f134012207f98b99e533ba573" shape="rect">NCT07258290</a>), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). </p><p> <b>Dr. Itsik Ben-Dor</b>, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html Tue, 23 Jun 2026 06:30:00 -0400 A.20911674 A.32270749 A.42215842 O.00001053 O.00042786 O.00134791 O.38131402 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html <p class="bwalignc"> <i>Enrollment completed ahead of schedule in BIOMAG™-II</i> </p><p class="bwalignc"> <i>Positive four-year BIOMAG™-I results recently reported</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290&amp;esheet=54558134&amp;newsitemid=20260623597311&amp;lan=en-US&amp;anchor=NCT07258290&amp;index=1&amp;md5=96a5d16f134012207f98b99e533ba573" shape="rect">NCT07258290</a>), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). </p><p> <b>Dr. Itsik Ben-Dor</b>, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html Tue, 23 Jun 2026 06:30:00 -0400 A.20911674 A.32270749 A.42215842 O.00001053 O.00042786 O.00134791 O.38131402 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html <p class="bwalignc"> <i>Enrollment completed ahead of schedule in BIOMAG™-II</i> </p><p class="bwalignc"> <i>Positive four-year BIOMAG™-I results recently reported</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290&amp;esheet=54558134&amp;newsitemid=20260623597311&amp;lan=en-US&amp;anchor=NCT07258290&amp;index=1&amp;md5=96a5d16f134012207f98b99e533ba573" shape="rect">NCT07258290</a>), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). </p><p> <b>Dr. Itsik Ben-Dor</b>, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html Tue, 23 Jun 2026 06:30:00 -0400 A.20911674 A.32270749 A.42215842 O.00001053 O.00042786 O.00134791 O.38131402 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html <p class="bwalignc"> <i>Enrollment completed ahead of schedule in BIOMAG™-II</i> </p><p class="bwalignc"> <i>Positive four-year BIOMAG™-I results recently reported</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290&amp;esheet=54558134&amp;newsitemid=20260623597311&amp;lan=en-US&amp;anchor=NCT07258290&amp;index=1&amp;md5=96a5d16f134012207f98b99e533ba573" shape="rect">NCT07258290</a>), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). </p><p> <b>Dr. Itsik Ben-Dor</b>, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html Tue, 23 Jun 2026 06:30:00 -0400 A.20911674 A.32270749 A.42215842 O.00001053 O.00042786 O.00134791 O.38131402 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html <p class="bwalignc"> <i>Enrollment completed ahead of schedule in BIOMAG™-II</i> </p><p class="bwalignc"> <i>Positive four-year BIOMAG™-I results recently reported</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290&amp;esheet=54558134&amp;newsitemid=20260623597311&amp;lan=en-US&amp;anchor=NCT07258290&amp;index=1&amp;md5=96a5d16f134012207f98b99e533ba573" shape="rect">NCT07258290</a>), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). </p><p> <b>Dr. Itsik Ben-Dor</b>, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html Tue, 23 Jun 2026 06:30:00 -0400 A.20911674 A.32270749 A.42215842 O.00001053 O.00042786 O.00134791 O.38131402 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html <p class="bwalignc"> <i>Enrollment completed ahead of schedule in BIOMAG™-II</i> </p><p class="bwalignc"> <i>Positive four-year BIOMAG™-I results recently reported</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290&amp;esheet=54558134&amp;newsitemid=20260623597311&amp;lan=en-US&amp;anchor=NCT07258290&amp;index=1&amp;md5=96a5d16f134012207f98b99e533ba573" shape="rect">NCT07258290</a>), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). </p><p> <b>Dr. Itsik Ben-Dor</b>, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html Tue, 23 Jun 2026 06:30:00 -0400 A.20911674 A.32270749 A.42215842 O.00001053 O.00042786 O.00134791 O.38131402 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html <p class="bwalignc"> <i>Enrollment completed ahead of schedule in BIOMAG™-II</i> </p><p class="bwalignc"> <i>Positive four-year BIOMAG™-I results recently reported</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290&amp;esheet=54558134&amp;newsitemid=20260623597311&amp;lan=en-US&amp;anchor=NCT07258290&amp;index=1&amp;md5=96a5d16f134012207f98b99e533ba573" shape="rect">NCT07258290</a>), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). </p><p> <b>Dr. Itsik Ben-Dor</b>, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html Tue, 23 Jun 2026 06:30:00 -0400 A.20911674 A.32270749 A.42215842 O.00001053 O.00042786 O.00134791 O.38131402 TFX http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html <p class="bwalignc"> <i>Enrollment completed ahead of schedule in BIOMAG™-II</i> </p><p class="bwalignc"> <i>Positive four-year BIOMAG™-I results recently reported</i> </p> <p> WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290&amp;esheet=54558134&amp;newsitemid=20260623597311&amp;lan=en-US&amp;anchor=NCT07258290&amp;index=1&amp;md5=96a5d16f134012207f98b99e533ba573" shape="rect">NCT07258290</a>), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). </p><p> <b>Dr. Itsik Ben-Dor</b>, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of http://www.streetinsider.com/Press+Releases/Teleflex+Initiates+Enrollment+in+Global+BIOMAG%E2%84%A2%E2%80%91III+Pivotal+Trial+of+Freesolve%E2%84%A2+Resorbable+Magnesium+Scaffold/26675505.html Tue, 23 Jun 2026 06:30:00 -0400 A.20911674 A.32270749 A.42215842 O.00001053 O.00042786 O.00134791 O.38131402 TFX